# 510(k) Summary

This summary of $5 1 0 ( \mathbf { k } )$ safcty and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.

The assigned 510(k) number is: K083746

1. Date of Summary: August 17, 2010

2. Submitted by: Princeton BioMeditech Corporation 4242 U.S. Hwy 1, Monmouth Jct., NJ 08852 Phone: 732-274-1000 Fax: 732-274-1010

Contact Person: Jemo Kang, Ph.D., j.kang@pbmc.com Alternate Contact Person: Kyung-ah Kim, Ph.D., kakim@pbmc.com

3.Device Name: Trade Names: BioSign® Flu $\mathbf { A } { \ + } \mathbf { B }$ EPY StatusTM Flu A & B Common or Usual Name: Influenza test Classification Name: Influenza virus serological reagents (21CFR 866.3330)

4. Identification of legally marketed devices to which claims of equivalence are made: K053146: QuickVue Influenza $\mathbf { A } { + } \mathbf { B }$ Test by Quidel Corp.

Device Description:

$\mathsf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { \sf + } \mathbf { B }$ is an immuno-chromatographic test for the rapid, qualitative detcction of influenza A and B. The test device has two test lines, thereby allowing the separate identification of type A and/or type B viral antigens from the same specimen.

In the test procedure, a specimen is collected and placed into the Extraction Well of the test device containing extraction solution for one minute, during which time antigen is extracted from disrupted virus particles. The test device is then raised, tapped and laid back down onto a level surface to allow the solution in the Extraction Well to migrate through the pads containing lyophilized detector antibodies conjugated to gold dye and then through the test membrane. If influenza antigens are present in the specimen, they will react with anti-influenza antibody coupled to gold dye particles, migrate through the membrane as antigen-antibody-dye complexes, bind to the immobilized anti-influenza antibody on the membrane, and generate a colored line in the Test line position (A and/or B). The rest of the sample and unbound/bound dye complexes continue to migrate to the Control line position, where antibody to the antiinfluenza antibody is immobilized, and anti-influenza antibody-unbound/bound dye complexes form the Control line (internal procedural control).

6Intended Use:

The BioSign® Flu $\mathbf { A } { + } \mathbf { B }$ tet i n nviorapi qualative test that detet iluenza tye A an type B antigens dircctly from nasal swab, nasopharyngeal swab, and nasopharyngcal aspirate/wash specimens obtained from patient with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. A negative test result is presumptive and it is recommended these results be confirmed by viral culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.

# 7. Technological Characteristics

Both BioSign® Flu $\mathbf { A } { + } \mathbf { B }$ and the predicate, QuickVue® Influenza $\mathbf { A } { \ + } \mathbf { B }$ tests are in vitro rapid qualitative tests that detect influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens. The scientific principle of both tests is a solid phase chromatographic immunoassay. Both tests are lateral flow rapid assays that employ specific antibodies immobilized onto solid phases to capture and visualize influenza nucleoprotein antigens.

# 8Performance Summary

# Clinical Study

A prospective clinical study was conducted from January 2007 to March 2008 and during March and April 2009 to determine the performance of BioSign® Flu $\mathbf { A } { \ + } \mathbf { B }$ for aspirate, nasopharyngeal swab, and nasal swab specimens. The samples were collected at 5 sites in the USA from patients who visited physicians' offices and clinics with signs and symptoms of respiratory infection during the study period. All collected samples were tested with ${ \dot { \mathbf { B i o S i g n } } } ^ { \otimes }$ Flu $\mathbf { A } { + } \mathbf { B }$ , and were cultured to confirm the results of BioSign® Flu $\mathbf { A } { + } \mathbf { B } .$ The total number of patients tested was 862, of which $3 0 \%$ were 5 and younger, $3 8 \%$ were 6-21 years old, and the rest were older than 21. Forty eight (48) percent were male and $52 \%$ were female.

The combined data from all sites of the prospective study are presented in the tables below.

The samples that produced discrepant results between BioSign Flu $\mathbf { A } { + } \mathbf { B }$ and viral culture were further analyzed with proFLU plus by Prodesse (real time RT-PCR, PCR hereafter). These results are presented in the footnote below each table.

# Nasopharyngeal Aspirate Sample :

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture)Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>Sensitivity:91.6%95%CI: 83.6-99.6%</td></tr><tr><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>1**</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>Specificity:97.5%95% CI:96.5-98.5%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>241</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=2 colspan=3>Reference (Virus Culture)Results</td><td></td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>30*</td><td rowspan=1 colspan=1>71.:</td><td rowspan=1 colspan=1>Sensitivity:95.3%95% CI: 92.1-98.5%</td></tr><tr><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>2**</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>Specificity:85.7%95% Cl: 83.3-88.1%</td></tr><tr><td rowspan=1 colspan=1>Totai</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1></td></tr></table>

f1. I " • :

\*O 30 discrepant results, 22 were positive by both BioSign and PCR $\yen 02$ discrepant results, all6 wee positive by BioSig and by PCR \*\* Of 2 discrepant results, 1 was negative by both BioSign and PCR The discrepant sample was positive by PCR

# Nasopharyngeal Sample

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture)Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>51*</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>Sensitivity:89.6%95% CI: 84.0-95.2%</td></tr><tr><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>Specificity:77.0%95% Cl: 74.2-79.8%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1></td></tr></table>

\*Of 51 discrepant results, 41 were positive by both BioSign and PCR \*\* Of 3 discrepant results, 1 was negative by both BioSign and PCR

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture)Resuits</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>15*</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>Sensitivity:86.8%95%CI: 81.4-92.2%</td></tr><tr><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>5**</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>203</td><td rowspan=1 colspan=1>Specificity:92.9%95% Cl: 91.2-94.6%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1></td></tr></table>

\*Of the 15 discrepant results, 8 were positive by both BioSign and PCR \*\*Of the 5 discrepant results, 2 were negative by both BioSign and PCR

# Nasal Swab Sample

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture)Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>80*</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>Sensitivity:91.7%95%&quot;Cl: 78.2-97.1%</td></tr><tr><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>245</td><td rowspan=1 colspan=1>Specificity:75.2%95% CI: 70.2-79.6%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>322</td><td rowspan=1 colspan=1>358</td><td rowspan=1 colspan=1></td></tr></table>

$\yen 020$ discrepant results, 65 were positive by both BioSign and PCR $* *$ Of 3 discrepant results, all 3 were positive by PCR

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture)Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Performance</td></tr><tr><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>40*</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>Sensitivity:82.4%95%CI: 59.0-93.8%</td></tr><tr><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>301</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>Specificity:88.3%95% Cl: 84.4-91.3%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>341</td><td rowspan=1 colspan=1>358</td><td rowspan=1 colspan=1></td></tr></table>

\*Of 40 discrepant results, 18 were positive by both BioSign and PCR \*\*O 3 discrepant results, 1 was negative by both BioSign and PCR

As further verification of the PCR test results shown from the samples with discrepant results between BioSign and viral culture, available archived remnant samples from the clinical studies with concordant results were also tested by PCR. The specificity for both Flu A and Flu B was $100 \%$ , while the sensitivity for Flu A was $90 \%$ and the sensitivity for Flu B was $9 1 . 7 \%$ .

# Archived Sample Test

Eighty (80) frozen archived samples originally obtained from influenza positive patients visiting Columbia NY Presbyterian Hospital and confirmed as positive for either influenza A or Influenza B by viral culture were tested with BioSign Flu $\mathbf { A } { + } \mathbf { B }$ .

The tables below present test results with archived samples.

Aspirate Sample   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture) Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Agreement</td></tr><tr><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>•  1150</td><td rowspan=1 colspan=1>;}           •-100%</td></tr><tr><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture) Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Agreement</td></tr><tr><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td></tr></table>

Swab Sample.. . .…:   

<table><tr><td rowspan=1 colspan=1>T</td><td rowspan=1 colspan=3>Reference (Virus Culture) Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+ B</td><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Agreement</td></tr><tr><td rowspan=1 colspan=1>Flu APositive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Flu ANegative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Reference (Virus Culture) Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BioSignFlu A+B</td><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Agreement</td></tr><tr><td rowspan=1 colspan=1>Flu BPositive</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Flu BNegative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td></tr></table>

# Reproducibility Study

The reproducibility study for the $\mathrm { B i o S i g n } ^ { \mathfrak { P } }$ Flu $\mathbf { A } { + } \mathbf { B }$ test was conducted at two Physicians' Offices and one laboratory using a panel of 180 coded specimens for each site. Testing was performed by two people for five days at each site following the same test protocol as would be used for fresh patient sample. The panel contained high negative, low positive and moderate positive specimens. Each specimen level was tested at each site in replicates of 15 over a period of five days.

The results obtained at each site agreed $100 \%$ with the expected results. No differences were observed within run (15 replicates), between runs (three different days), or bctween sites (three POL sites and one lab).

# Analytical Sensitivity

Limit of Detection (LOD)

The LODs were determined for each of the two strains selected from the influenza type A and type B strains. The sensitivity level of each selected viral strain was tested 60 timcs to confirm the sensitivity level as LOD level, which gives $9 5 \%$ detection rate.

All four viral strains tested were detected $9 6 . 7 \%$ of the time in 60 replicates at the levcl listed in the table below.

<table><tr><td rowspan=1 colspan=1>Influenza Type</td><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>TCIDs0/mL</td><td rowspan=1 colspan=1>#Positive/#Total</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/PR/8/34(H1N1)</td><td rowspan=1 colspan=1>1.05× 10^2$</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Victoria/3/75(H3N2)</td><td rowspan=1 colspan=1>9.95 × 10</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Taiwan/2/62</td><td rowspan=1 colspan=1>1.58× 10^3</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Maryland/1/59</td><td rowspan=1 colspan=1>1.99× 101</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7</td></tr></table>

# Analytical Inclusivity

The analytical inclusivity was established for a total of 21 influenza strains: 11 strains of influenza A type and 10 strains of influenza B type. The results are shown in the table below.   

<table><tr><td rowspan=1 colspan=1>InfluenzaType</td><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>TCID50/mL</td><td rowspan=1 colspan=1>InfluenzaType</td><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/PR/8/34(H1N1)</td><td rowspan=1 colspan=1>1.05 × 10^2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Lec/40</td><td rowspan=1 colspan=1>5.00 × 100</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/FM/1/47(H1N1)</td><td rowspan=1 colspan=1>1.73 × 10&#x27;</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Allen/45</td><td rowspan=1 colspan=1>1.58× 100$</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/NWS/33(H1NI)</td><td rowspan=1 colspan=1>4.10 × 103</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/GL/1739/54</td><td rowspan=1 colspan=1>9.95× 10^{2</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Hong Kong/8/68(H3N2)</td><td rowspan=1 colspan=1>8.5× 10^{2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Taiwan/2/62</td><td rowspan=1 colspan=1>1.58× 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Denver/1/57(H1N1)</td><td rowspan=1 colspan=1>7.20 × 100$</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Maryland/1/59</td><td rowspan=1 colspan=1>1.99 × 10&#x27;</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Aichi/2/68(H3N2)</td><td rowspan=1 colspan=1>9.95 × 10°</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Mass/3/66</td><td rowspan=1 colspan=1>5.00 × 10{</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Port Chalmers/1/73</td><td rowspan=1 colspan=1>1.99× 102</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/R22 Barbara</td><td rowspan=1 colspan=1>1.6× 10-1</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Victoria/3/75(H3N2)</td><td rowspan=1 colspan=1>9.95 × 101</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/R75</td><td rowspan=1 colspan=1>2.94 × 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/New Jersey/8/76(H1N1)</td><td rowspan=1 colspan=1>9.95 × 101</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Russia/69</td><td rowspan=1 colspan=1>3.16× 10^</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/WS/33(HINI)</td><td rowspan=1 colspan=1>5.00 × 101</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B/Hong Kong/5/72</td><td rowspan=1 colspan=1>2.88 × 101</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Swine/1976/31</td><td rowspan=1 colspan=1>1.58× 10{2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>cYanmaGelo</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>2009 HIN1 Clinical Isolate*(Swine Origin Influenza A)</td><td rowspan=1 colspan=1>1.00 x 103</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

1.1 !!

<table><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>2009 H1N1 Clinical Isolate*(Swine Origin Influenza A)</td><td rowspan=1 colspan=1>1.00 × 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/CA/07/2009(H1N1)</td><td rowspan=1 colspan=1>6.15 × 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/CA/08/2009(H1N1)</td><td rowspan=1 colspan=1>9.31 × 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/NY/18/2009(H1N1)</td><td rowspan=1 colspan=1>2.5×10^3}$</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Mexico/4108/2009(H1N1)</td><td rowspan=1 colspan=1>8.51× 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/CA/07/2009 NYC, X-179A(HIN1)</td><td rowspan=1 colspan=1>1.08 × 103</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Virginia/ATCC2/2009(H1N1)</td><td rowspan=1 colspan=1>2.32 × 10³3</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>A/Virginia/ATCC3/2009(H1N1)</td><td rowspan=1 colspan=1>5.00 × 104</td></tr></table>

l so ulu niCulu  osiv    Inz t proFLU Influenza A Subtying

The performance of $\mathsf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { + } \mathbf { B }$ was evaluated with nasal and nasopharyngeal swab samples obtained from patients infected with the $2 0 0 9 \ \mathrm { H l N } 1$ influenza virus consisting of sixty six (66) frozen clinical Nasal and Nasopharyngeal samples that had previously tested positive for 2009 H1N1 by the cleared CDC RT-PCR test. The ${ \dot { \mathbf { B i o S i g n } } } ^ { \mathfrak { P } }$ Flu $\mathbf { A } { + } \mathbf { B }$ test detected $7 1 \%$ (47/66) of the CDC RT-PCR test positive specimens. The detection rate was $9 1 \%$ with the higher tittered specimens and $3 8 \%$ with the lower tittered specimens.

# NOTE:

The performancc characteristics of the tcst with cultured avian influenza A subtype H5N1 virus, or with specimens from human infected with H5N1 or other avian influenza viruses has not been established........ $\langle i ^ { 1 } , \downarrow \downarrow 1 i \downarrow \ddots \downarrow \rangle$ EPY :'

# Analytical Specificity

# Cross-reactivity

The potential cross-reactivity of the non-influenza respiratory pathogens and other microorganisms with which the majority of the population may be infected was tested on the BioSign Flu $\mathbf { A } { + } \mathbf { B }$ test at medically relevant levels, $1 0 ^ { 6 } \mathsf { c f u / m L }$ for bacteria and $1 0 ^ { 5 } \mathrm { p f u / m L }$ for non-flu viruses. None of the organisms or viruses listed in the table below gave a positive result with $\mathbf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { + } \mathbf { B }$ at the tested concentration.

<table><tr><td rowspan=1 colspan=2>Viruses Tested</td></tr><tr><td rowspan=1 colspan=1>Adenovirus*</td><td rowspan=1 colspan=1>Measles**</td></tr><tr><td rowspan=1 colspan=1>Human coronavirus**</td><td rowspan=1 colspan=1>Human metapncumovirus**</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus**</td><td rowspan=1 colspan=1>Mumps virus**</td></tr><tr><td rowspan=1 colspan=1>Enterovirus**</td><td rowspan=1 colspan=1>Respiratory syncytial virus; Type B*</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus**</td><td rowspan=1 colspan=1>Rhinovirus; Type 1A**</td></tr><tr><td rowspan=1 colspan=1>Human parainfluenza;Type 1, 2 and 3*</td><td></td></tr></table>

\*\*In te study the virus was confirmed using commercially available CR (not approved by FDA). \* In the study the virus was confirmed using FDA approved immuno-fluorecence assay.

<table><tr><td rowspan=1 colspan=2>Bacteria Tested</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=1>Neisseria sp.</td></tr><tr><td rowspan=1 colspan=1>Chlamydia pneumoniae</td><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium sp.</td><td rowspan=1 colspan=1>Staphylococcus aureus: Protein A Producer</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>Staphylococcus epidermidis</td></tr><tr><td rowspan=1 colspan=1>Hemophilus influenzae</td><td rowspan=1 colspan=1>Streptococcus pneumoniae</td></tr><tr><td rowspan=1 colspan=1>Lactobacillus sp.</td><td rowspan=1 colspan=1>Streptococcus pyogenes</td></tr><tr><td rowspan=1 colspan=1>Legionella spp</td><td rowspan=1 colspan=1>Streptococcus salivarius</td></tr><tr><td rowspan=1 colspan=1>Moraxella catarrhalis</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycobacterium tuberculosis avirulent</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitides</td><td></td></tr></table>

# Interference

The interference study was conducted using mcdically relevant concentrations of the potentially interfering substances listed below with two strains each of influenza type A and type $\mathbf { B }$ to assess thc potential interference of the substances on the performance of the $\mathbf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { \ + } \mathbf { B }$ EY test.

The test was conducted by spiking each substance into samples containing the lowest detectable virus level of influenza Type A or Type B for the positive interference testing and into samples without influenza virus for the negative interference testing. Each substance had no inhibitory effect on the $\mathbf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { + } \mathbf { B }$ test at the concentration listed in the table below.

<table><tr><td rowspan=1 colspan=1>Substances Tested</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>Mucin</td><td rowspan=1 colspan=1>1 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Phenylephrine</td><td rowspan=1 colspan=1>10 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Oxymetazoline</td><td rowspan=1 colspan=1>10 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride with preservative</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Beclomethasone</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Dexamethasone</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Flunisolide</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Triamcinolone</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Budesonide</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Mometasone</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Fluticasone</td><td rowspan=1 colspan=1>0.5 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Luffa opperculata, sulfur</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Galphimia glauca</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Histaminum hydrochloricum i i  . . .              ;&quot;</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Live intranasal influenza virus vaccine</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Benzocaine</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Menthol</td><td rowspan=1 colspan=1>l mg/mL</td></tr><tr><td rowspan=1 colspan=1>Zanamivir</td><td rowspan=1 colspan=1>l mg/mL</td></tr><tr><td rowspan=1 colspan=1>Mupirocin</td><td rowspan=1 colspan=1>1 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>1 mg/mL</td></tr></table>

Dr. Kyung-ah Kim   
Associate Director   
Princeton BioMeditech Corporation   
4242 U.S Route 1   
Monmouth Junction, NJ 08852-1905

NOV 10 2010

Re: k083746 Trade/Device Name: BioSign Flu $\mathbf { A } { + } \mathbf { B }$ Test Regulation Number: 21 CFR 866.3330 Regulation Name: Influenza Virus Serological Reagents Regulatory Class: Class I Product Code: GNX Dated: November 8, 2010 Received: November 9, 2010

Dear Dr. Kyung-ah Kim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K083746

Device Name: BioSign® Flu A+B, Status Flu A & B

Indications For Use:

The $\mathbf { B i o S i g n } ^ { \otimes }$ Flu $\mathbf { A } { + } \mathbf { B }$ test is an in vitro rapid qualitative test that detects influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab, nasopharyngeal aspirate/wash specimens of patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. A negative test result is presumptive and it is recommended these results be confirmed by viral culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.